RE:ONCY presents 2 posters at ASCO 2024A primer on pancreatic cancer .... and current treatment options.
https://www.cancer.gov/types/pancreatic/patient/pancreatic-treatment-pdq
Stage IV (metastatic) pancreatic cancer has a five-year survival rate of 1 percent. The average patient diagnosed with late-stage pancreatic cancer will live for about one year after diagnosis.
https://www.hopkinsmedicine.org/health/conditions-and-diseases/pancreatic-cancer/pancreatic-cancer-prognosis
https://www.webmd.com/cancer/pancreatic-cancer/pancreatic-cancer-treatments-stage
15 months into treatment (based on a September 18, 2023 data cut-off date), the PDAC arm of the GOBLET study demonstrated findings that showed an impressive overall response rate of 7.2 months of median progression-free survival, interim median overall survival of 10.6 months, surpassing historical norms by >25%, and the resulting in the expansion of both pre-existing and new T-cell clones - all demonstrating the effectiveness of the pelareorep + atezolizumab + chemotherapy immunotherapy combination versus chemotherapy alone in the most difficult (rare) disease scenario with a current "unmet treatment need".
Consequently, systemic treatment plays an important role in the treatment of metastatic pancreatic cancer (mPDAC).
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8526424/
The 13 evaluable patients enrolled in the first stage of the GOBLET-1 PDAC study have been evaluated based on a September 18, 2023 data cut-off date. The enrolled patient population included 93% of patients with metastatic disease (69% with liver metastases) and baseline ECOG scores of 0 (31%) and 1 (69%), with an average age of 61.2 years.
https://oncolyticsbiotech.com/press_releases/oncolytics-presents-positive-updated-pancreatic-cancer-data-from-goblet-phase-1-2-study-at-esmo/